Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BIIE-0246
Cat. No.:
OB0425LY-011
Appearance:
Solid
Purity:
99.1%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
BIIE-0246 is a selective NPY2R antagonist that decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated.
Synonyms:
246146-55-4; BIIE 0246; BIIE0246; Ar-H-053591; (2S)-5-(Diaminomethylideneamino)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-2-[[2-[1-[2-oxo-2-[4-(6-oxo-5,11-dihydrobenzo[c][1]benzazepin-11-yl)piperazin-1-yl]ethyl]cyclopentyl]acetyl]amino]pentanamide; N-[(1S)-4-[(Amino-iminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-cyclopentaneacetamide
CAS No.:
246146-55-4
Compound CID:
9811493
Formula:
C49H57N11O6
Formula Weight:
896.05
Specification
Target:
Neuropeptide Y receptor
Pathway:
GPCR/G protein; Neuronal signaling
Storage:
Storage at -20°C.
Applications:
BIIE-0246 has been extensively studied for use in models of cardiovascular and obesity diseases.
